Flexible Access to AJICAP™ Technology

We offer flexible access to AJICAP™ conjugation and linker technologies through licensing and technology transfer models tailored to your needs. Your program may begin with feasibility evaluation and sample preparation before progressing to broader development through licensing. We provide process development, analytical support, and technology transfer expertise to efficiently integrate the technology into your workflows.

Commercial Licensing Model

AJICAP™ licensing is not a fixed protocol. Our chemistry team works with licensees to adapt the process for specific antibodies, payloads, equipment configurations, and regulatory requirements.

GMP Manufacturing

Manufacturing Process Rights

Full AJICAP™ process rights for GMP clinical and commercial manufacturing

Technology Transfer

Complete tech transfer package – process descriptions

Process Optimization

Ongoing technical support and process optimization access

Partner Support

Manufacture at your facility or designated partner CDMO

Customer Development Program

Integrating AJICAP™ into Your ADC Therapy

AJICAP™ supports the integration of conjugation and linker technologies into customer development programs through a structured technology transfer and process adaptation approach. We work with customers to map the manufacturing process and identify development activities required for implementation. Our structured approach helps reduce development risk and supports efficient integration into manufacturing workflows.

Customized to Remove Constraints

AJICAP™ is designed to provide flexibility across a wide range of bioconjugate development programs. Depending on the conjugation strategy, the technology is compatible with diverse antibody formats, linker-payload designs, and customer-specific payloads.

Support Multiple DAR Formats

The AJICAP™ platform can support multiple DAR formats including DAR1, DAR2, DAR4, dual-payload conjugates, and higher DAR configurations.

Works on Native IgG

AJICAP™ adapts to your antibody — no upstream engineering or modification required. Compatible across IgG isotypes; confirm subtype range with science team for your specific program.

Any Linker-Payload Combination

AJICAP™ conjugation is compatible with the linker-payload system your program requires — auristatins, maytansinoids, camptothecins/DXd, PBDs, and others. Confirm specific combinations with the team.

Ready to Move Forward?

Multiple licensing models, full tech transfer support, from first evaluation through commercial manufacturing.

Request a Licensing Guide

Resources

Frequently Asked Questions

How is intellectual property protected with AJICAP™ technology transfer?

AJICAP™ core technology and related intellectual property are owned by Ajinomoto Bio-Pharma Services. Product-specific development and associated intellectual property remain with the customer. Confidentiality and intellectual property considerations are addressed through appropriate contractual agreements and technology transfer processes.

What is the typical transfer timeline for AJICAP™?

Technology transfer timelines for AJICAP™ vary depending on program scope, process complexity, manufacturing strategy, and development stage. Ajinomoto Bio-Pharma Services’ transfer activities are planned on a project-specific basis to support efficient implementation and manufacturing readiness.

Can the AJICAP™ process scale with my program?

Yes. Ajinomoto Bio-Pharma Services’ AJICAP™ technologies can be applied from early-stage evaluation through clinical and commercial manufacturing. Process development and technology transfer support are available to facilitate scale-up, while manufacturing can be performed by qualified AJICAP™ partner CDMOs or customer-selected manufacturing partners. This flexible approach enables efficient progression throughout the product lifecycle.